Healthcare provider profile · identity verified

Savanna Griffith, DO

Family Practice · SNOHOMISH, WA · NPI 1740694934

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	350	123
Levothyroxine Sodium	Levothyroxine Sodium	254	80
Lisinopril	Lisinopril	235	76
Losartan Potassium	Losartan Potassium	232	80
Amlodipine Besylate	Amlodipine Besylate	211	72
Omeprazole	Omeprazole	187	66
Gabapentin	Gabapentin	138	50
Trazodone Hcl	Trazodone Hcl	124	48
Rosuvastatin Calcium	Rosuvastatin Calcium	122	45
Hydrochlorothiazide	Hydrochlorothiazide	117	35
Sertraline Hcl	Sertraline Hcl	114	42
Metformin Hcl Er	Metformin Hcl	108	35
Metoprolol Succinate	Metoprolol Succinate	107	41
Bupropion Xl	Bupropion Hcl	94	34
Alendronate Sodium	Alendronate Sodium	82	24
Donepezil Hcl	Donepezil Hcl	80	26
Escitalopram Oxalate	Escitalopram Oxalate	77	25
Albuterol Sulfate Hfa	Albuterol Sulfate	76	46
Atenolol	Atenolol	73	23
Duloxetine Hcl	Duloxetine Hcl	72	22
Potassium Chloride	Potassium Chloride	70	25
Tizanidine Hcl	Tizanidine Hcl	68	20
Glipizide Er	Glipizide	61	15
Simvastatin	Simvastatin	61	17
Famotidine	Famotidine	56	23
Metformin Hcl	Metformin Hcl	55	20
Allopurinol	Allopurinol	53	18
Eliquis	Apixaban	53	16
Tramadol Hcl	Tramadol Hcl	51	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	50	14
Pravastatin Sodium	Pravastatin Sodium	47	22
Tamsulosin Hcl	Tamsulosin Hcl	47	17
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	44	13
Oxybutynin Chloride	Oxybutynin Chloride	39	19
Fluticasone Propionate	Fluticasone Propionate	37	23
Fluoxetine Hcl	Fluoxetine Hcl	36	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	36	12
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	34	31
Baclofen	Baclofen	33	suppressed
Estradiol	Estradiol	33	suppressed
Lovastatin	Lovastatin	33	11
Furosemide	Furosemide	32	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	14
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	27	suppressed
Ezetimibe	Ezetimibe	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Doxepin Hcl	Doxepin Hcl	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	13
Nystatin	Nystatin	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Nifedipine Er	Nifedipine	17	suppressed
Azithromycin	Azithromycin	16	15
Pregabalin	Pregabalin	16	suppressed
Alprazolam	Alprazolam	15	14
Buspirone Hcl	Buspirone Hcl	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	12
Valacyclovir	Valacyclovir Hcl	15	suppressed
Carvedilol	Carvedilol	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Lansoprazole	Lansoprazole	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Terbinafine Hcl	Terbinafine Hcl	14	13
Finasteride	Finasteride	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Glipizide	Glipizide	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	11
Xarelto	Rivaroxaban	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Spironolactone	Spironolactone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error